The prescribing information for Qelbree (viloxazine extended-release capsules) has been updated with new pharmacodynamic and lactation data.

Takeda has decided to withdraw its cancer drug Exkivity from the market, after a trial that was supposed to confirm its efficacy failed to deliver a positive result. Following discussions with the ...

The therapy – recently approved for the same indication in the US – moves into a setting recently vacated by Takeda’s Exkivity (mobocertinib), which was pulled from the market last year ...